Contera Pharma enters partnership with Vernalis Research on undisclosed disease

The two companies will collaborate on a small RNA-targeted molecule for a disease with no current treatment options, but that’s all Contera Pharma’s chief scientific officer is willing to say.

Kenneth Vielsted Christensen, chief scientific officer of Contera Pharma | Photo: Contera Pharma / PR

Contera Pharma hasn’t been idle in recent time. The biotech company, which has been working on an initial public offering in South Korea, has just entered another strategic partnership, this time with British firm Vernalis Research, according to a company press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs